NCM
ANIK icon

Noesis Capital Mangement’s Anika Therapeutics ANIK Stock Holding History

Noesis Capital Mangement’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Hold
19,400
– – 0.03% 107
2026
Q1 		$281K Hold
19,400
– – 0.04% 99
2025
Q4 		$186K Hold
19,400
– – 0.03% 132
2025
Q3 		$182K Hold
19,400
– – 0.03% 127
2025
Q2 		$205K Hold
19,400
– – 0.04% 126
2025
Q1 		$292K Buy
+19,400
New +$323K 0.06% 94

Other funds holding ANIK

CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
IP
Indivisible Partners Clearwater, Florida $1.77B AUM
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
RS
R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Noesis Capital Mangement's ANIK Position: Q2 2026 in Review

Noesis Capital Mangement held its Anika Therapeutics (ANIK) position steady in Q2 2026 at 19,400 shares worth $284K. The position accounts for 0.03% of the portfolio, ranked #107.

Noesis Capital Mangement first reported a position in ANIK in Q1 2025 and has held it in 6 quarters since. The position peaked at $292K in Q1 2025. 30 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Noesis Capital Mangement held 19,400 shares of Anika Therapeutics worth $284K as of Q2 2026.
  • Noesis Capital Mangement left its Anika Therapeutics share count unchanged in Q2 2026.
  • Anika Therapeutics made up 0.03% of Noesis Capital Mangement's portfolio in Q2 2026, its #107 holding.
  • Noesis Capital Mangement first reported a position in Anika Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Noesis Capital Mangement's Anika Therapeutics position peaked at $292K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Noesis Capital Mangement's 13F filing for Q2 2026, filed 4 Aug 2026.